Temporal Trends and Determinants of Low-Dose Estrogen-Progestin Prescription in Japan During 2014–2022: An Ecological Study Using a Nationwide Claims Database

IF 1.5 4区医学 Q3 OBSTETRICS & GYNECOLOGY

Journal of Obstetrics and Gynaecology Research Pub Date : 2025-10-05 DOI:10.1111/jog.70093

Keiko Takata, Mariko Ogawa, Toshifumi Takahashi

{"title":"Temporal Trends and Determinants of Low-Dose Estrogen-Progestin Prescription in Japan During 2014–2022: An Ecological Study Using a Nationwide Claims Database","authors":"Keiko Takata, Mariko Ogawa, Toshifumi Takahashi","doi":"10.1111/jog.70093","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>This study aimed to evaluate the trends and regional disparities in low-dose estrogen-progestin (LEP) prescription in Japan from 2014 to 2022 and the factors contributing to these disparities.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>LEP prescription data were obtained from the National Health Insurance Claims and Specific Health Examination Database; the prescriptions per 1000 women aged 10–54 years were calculated. Trends were analyzed in terms of the overall volume, age group distribution, and formulation type. The regional distribution in 2022 was also examined; the factors influencing regional differences were identified using multiple regression analysis.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>LEP prescriptions showed a significant annual increase (<i>p</i> < 0.05), rising approximately five-fold over 9 years. A significant increase was observed in all age groups, except for those in their 50s (<i>p</i> < 0.05). Ethinylestradiol 0.035 mg/norethisterone 1 mg (<i>p</i> < 0.005) and ethinylestradiol 0.02 mg/drospirenone 3 mg (cyclic dosing regimen) (<i>p</i> < 0.001) usage declined. Conversely, ethinylestradiol 0.02 mg/drospirenone 3 mg (continuous dosing regimen) and ethinylestradiol 0.02 mg/levonorgestrel 0.09 mg usage increased significantly (<i>p</i> < 0.05). In 2022, regional disparities in LEP prescriptions reached a maximum of 2.7-fold. These disparities were not associated with the number of obstetricians and gynecologists and women's health specialists. However, the prescription of EE 0.02 mg/drospirenone 3 mg (continuous dosing regimen) showed a significant association with the number of women's health specialists (<i>p</i> = 0.002).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>This study provides the first comprehensive analysis of real-world LEP prescription patterns in Japan, revealing significant regional disparities.</p>\n </section>\n </div>","PeriodicalId":16593,"journal":{"name":"Journal of Obstetrics and Gynaecology Research","volume":"51 10","pages":""},"PeriodicalIF":1.5000,"publicationDate":"2025-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Obstetrics and Gynaecology Research","FirstCategoryId":"3","ListUrlMain":"https://obgyn.onlinelibrary.wiley.com/doi/10.1111/jog.70093","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim

This study aimed to evaluate the trends and regional disparities in low-dose estrogen-progestin (LEP) prescription in Japan from 2014 to 2022 and the factors contributing to these disparities.

Methods

LEP prescription data were obtained from the National Health Insurance Claims and Specific Health Examination Database; the prescriptions per 1000 women aged 10–54 years were calculated. Trends were analyzed in terms of the overall volume, age group distribution, and formulation type. The regional distribution in 2022 was also examined; the factors influencing regional differences were identified using multiple regression analysis.

Results

LEP prescriptions showed a significant annual increase (p < 0.05), rising approximately five-fold over 9 years. A significant increase was observed in all age groups, except for those in their 50s (p < 0.05). Ethinylestradiol 0.035 mg/norethisterone 1 mg (p < 0.005) and ethinylestradiol 0.02 mg/drospirenone 3 mg (cyclic dosing regimen) (p < 0.001) usage declined. Conversely, ethinylestradiol 0.02 mg/drospirenone 3 mg (continuous dosing regimen) and ethinylestradiol 0.02 mg/levonorgestrel 0.09 mg usage increased significantly (p < 0.05). In 2022, regional disparities in LEP prescriptions reached a maximum of 2.7-fold. These disparities were not associated with the number of obstetricians and gynecologists and women's health specialists. However, the prescription of EE 0.02 mg/drospirenone 3 mg (continuous dosing regimen) showed a significant association with the number of women's health specialists (p = 0.002).

Conclusion

This study provides the first comprehensive analysis of real-world LEP prescription patterns in Japan, revealing significant regional disparities.

查看原文本刊更多论文

2014-2022年日本低剂量雌激素-黄体酮处方的时间趋势和决定因素：一项使用全国索赔数据库的生态学研究

目的：本研究旨在评估2014 - 2022年日本低剂量雌激素-黄体酮（LEP）处方的趋势和地区差异以及造成这些差异的因素。方法：LEP处方数据来源于国家健康保险理赔与特殊健康检查数据库；计算每1000名10-54岁妇女的处方。分析了总体数量、年龄组分布和制剂类型的趋势。研究了2022年的区域分布；采用多元回归分析确定影响区域差异的因素。结论：本研究首次对日本现实世界LEP处方模式进行了综合分析，揭示了显著的地区差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Obstetrics and Gynaecology Research 医学-妇产科学

CiteScore

3.10

自引率

0.00%

发文量

376

审稿时长

3-6 weeks

期刊介绍： The Journal of Obstetrics and Gynaecology Research is the official Journal of the Asia and Oceania Federation of Obstetrics and Gynecology and of the Japan Society of Obstetrics and Gynecology, and aims to provide a medium for the publication of articles in the fields of obstetrics and gynecology. The Journal publishes original research articles, case reports, review articles and letters to the editor. The Journal will give publication priority to original research articles over case reports. Accepted papers become the exclusive licence of the Journal. Manuscripts are peer reviewed by at least two referees and/or Associate Editors expert in the field of the submitted paper.